Screener
BioCryst Pharmaceuticals BCRX Other income, net (Note 6)
Other income, net (Note 6) at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Interest expense | (21,712) | (21,582) | (41,491) | (45,076) |
| Foreign currency gains (losses), net | 27 | (63) | (198) | (62) |
| Loss on extinguishment of debt | — | (4,171) | — | (4,171) |
| Other income (expense), net | 260 | — | (1,202) | — |
| Total other expense, net | (18,991) | (23,300) | (38,201) | (43,769) |
| Income (loss) before income taxes | 79,474 | 6,486 | (641,334) | 7,244 |
| Income tax expense | 1,079 | 1,401 | 2,083 | 2,127 |
| Net income (loss) | $78,395 | $5,085 | $(643,417) | $5,117 |
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's other income, net (note 6)?
- BioCryst Pharmaceuticals (BCRX) reported other income, net (note 6) of $260K in Q2 2026.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.
Ask your AI about BioCryst Pharmaceuticals's other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude